An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients

Back to Search
Print
Bookmark Trial

NCT00235794

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Houston, Texas, 77030, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Prostatic Neoplasms
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically confirmed diagnosis of adenocarcinoma of the prostate gland via a minimum of 6 core biopsy samples.

- Subjects must be a candidate for radical prostatectomy

- No evidence of metastatic disease as determined by CT scans and bone scans

- More criteria apply

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects from whom sufficient diagnostic biopsy material is not available for full
characterization of the tumor


- Active Infection requiring antibiotic therapy, or serious intercurrent illness, active
bleeding, or ongoing urinary tract infection necessitating rapid or emergent surgical
resection


- Subjects who have had hormonal injection or implants which will last longer than 6
months


- More criteria apply

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

ClinicalTrials.gov_I[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Prostatic NeoplasmsStudy Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer NCT00137436
  1. Harvey, Illinois
  2. Tinley Park, Illinois
  3. Hobart, Indiana
  4. Munster, Indiana
  5. Durham, North Carolina
  6. Portland, Oregon
  7. Portland, Oregon
  8. Myrtle Beach, South Carolina
  9. Clarksville, Tennessee
  10. Franklin, Tennessee
  11. Gallarin, Tennessee
  12. Hermitage, Tennessee
  13. Lebanon, Tennessee
  14. Murfreesboro, Tennessee
  15. Nashville, Tennessee
  16. Nashville, Tennessee
  17. Nashville, Tennessee
  18. Nashville, Tennessee
  19. Smithville, Tennessee
  20. Smyrna, Tennessee
  21. Tullahoma, Tennessee
  22. Dallas, Texas
  23. Houston, Texas
  24. Madison, Wisconsin
Male
18 Years+
years
MULTIPLE SITES
Prostatic NeoplasmsAn Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients NCT00235794
  1. Houston, Texas
Male
18 Years+
years
MULTIPLE SITES
Prostatic NeoplasmsA Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) NCT02616185
  1. Morristown, New Jersey
  2. Whippany, New Jersey
  3. Tucson, Arizona
  4. Tucson, Arizona
  5. Golden, Colorado
  6. New Haven, Connecticut
  7. Bethesda, Maryland
  8. Bethesda, Maryland
  9. Creve Coeur, Missouri
  10. Saint Louis, Missouri
  11. Saint Louis, Missouri
  12. Saint Louis, Missouri
  13. Omaha, Nebraska
  14. Las Vegas, Nevada
  15. Morristown, New Jersey
  16. Morristown, New Jersey
  17. Rockaway, New Jersey
  18. Lake Success, New York
  19. New York, New York
  20. New York, New York
  21. New York, New York
  22. New York, New York
  23. Durham, North Carolina
  24. Durham, North Carolina
  25. Pittsburgh, Pennsylvania
  26. Seattle, Washington
  27. Seattle, Washington
Male
18 Years+
years
MULTIPLE SITES
Prostatic NeoplasmsStudy of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) NCT00313781
  1. Los Angeles, California
  2. New York, New York
  3. Cleveland, Ohio
  4. Cleveland, Ohio
  5. Orange Village, Ohio
  6. Philadelphia, Pennsylvania
  7. Montreal, Quebec
  8. Montreal, Quebec
  9. Berlin,
  10. Muenchen,
  11. Hospitalet de Llobregat, Barcelona
  12. A Coruña,
  13. Barcelona,
  14. St. Gallen,
  15. Sutton, Surrey
  16. Glasgow,
  17. Glasgow,
  18. Guildford,
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
Official Title  ICMJE An Open Label Study of Exploratory Pharmacogenomics and Pharmacologic Effects of Neoadjuvant Oral Temsirolimus in Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have a High Risk of Relapse
Brief Summary Open-label exloratory pharmacodynamic and pharmacogenomic study to evaluate teh biologic effects of 3 dose levels (1mg, 5 mg, and 15 mg) of temsirolimus administered orally once daily for approximately 4 weeks (+/- 2 weeks) before prostatectomy
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Prostatic Neoplasms
Intervention  ICMJE Drug: temsirolimus
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Estimated Enrollment  ICMJE
 (submitted: March 8, 2007)		50
Original Enrollment  ICMJE
 (submitted: October 6, 2005)		10
Actual Study Completion Date  ICMJE September 2007
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion criteria:

  • Histologically confirmed diagnosis of adenocarcinoma of the prostate gland via a minimum of 6 core biopsy samples.
  • Subjects must be a candidate for radical prostatectomy

  • No evidence of metastatic disease as determined by CT scans and bone scans

    • More criteria apply

Exclusion Criteria:

  • Subjects from whom sufficient diagnostic biopsy material is not available for full characterization of the tumor
  • Active Infection requiring antibiotic therapy, or serious intercurrent illness, active bleeding, or ongoing urinary tract infection necessitating rapid or emergent surgical resection

  • Subjects who have had hormonal injection or implants which will last longer than 6 months

    • More criteria apply
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00235794
Other Study ID Numbers  ICMJE 3066A1-132
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP